JP2019518713A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518713A5 JP2019518713A5 JP2018548878A JP2018548878A JP2019518713A5 JP 2019518713 A5 JP2019518713 A5 JP 2019518713A5 JP 2018548878 A JP2018548878 A JP 2018548878A JP 2018548878 A JP2018548878 A JP 2018548878A JP 2019518713 A5 JP2019518713 A5 JP 2019518713A5
- Authority
- JP
- Japan
- Prior art keywords
- trail
- polypeptide
- polypeptide chain
- amino acid
- monomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 96
- 229920001184 polypeptide Polymers 0.000 claims description 95
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 95
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims description 45
- 108700012411 TNFSF10 Proteins 0.000 claims description 45
- 239000000178 monomer Substances 0.000 claims description 28
- 230000035772 mutation Effects 0.000 claims description 28
- 230000000087 stabilizing effect Effects 0.000 claims description 28
- 238000006467 substitution reaction Methods 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 25
- 235000018102 proteins Nutrition 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 229940024606 amino acid Drugs 0.000 claims description 16
- 235000001014 amino acid Nutrition 0.000 claims description 16
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 12
- 229960000310 isoleucine Drugs 0.000 claims description 12
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 12
- 230000004927 fusion Effects 0.000 claims description 10
- 125000000539 amino acid group Chemical group 0.000 claims description 9
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 claims description 8
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 8
- 102000044949 human TNFSF10 Human genes 0.000 claims description 8
- 239000004474 valine Substances 0.000 claims description 8
- 238000002844 melting Methods 0.000 claims description 6
- 230000008018 melting Effects 0.000 claims description 6
- 239000013638 trimer Substances 0.000 claims description 6
- 238000006471 dimerization reaction Methods 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000000034 method Methods 0.000 description 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 1
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662309352P | 2016-03-16 | 2016-03-16 | |
| US62/309,352 | 2016-03-16 | ||
| US201662323501P | 2016-04-15 | 2016-04-15 | |
| US62/323,501 | 2016-04-15 | ||
| US201762445556P | 2017-01-12 | 2017-01-12 | |
| US62/445,556 | 2017-01-12 | ||
| PCT/US2017/022789 WO2017161173A1 (en) | 2016-03-16 | 2017-03-16 | Engineered trail for cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019518713A JP2019518713A (ja) | 2019-07-04 |
| JP2019518713A5 true JP2019518713A5 (cg-RX-API-DMAC7.html) | 2020-04-23 |
Family
ID=58413224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548878A Pending JP2019518713A (ja) | 2016-03-16 | 2017-03-16 | 癌療法のための改変ｔｒａｉｌ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20190077870A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3430034A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2019518713A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180127407A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108884142A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017234679A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3017622A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL261267A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018011219A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017161173A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108026181B (zh) * | 2015-10-22 | 2021-07-02 | 成都华创生物技术有限公司 | 一种TRAIL双靶点突变蛋白MuR6S4TR、其制备方法及其应用 |
| CN109641033A (zh) * | 2016-06-13 | 2019-04-16 | 梅里麦克制药股份有限公司 | 用基于trail的治疗剂或死亡受体激动剂选择和治疗患者的方法 |
| CN109125709B (zh) * | 2018-08-23 | 2021-10-22 | 成都华创生物技术有限公司 | Trail突变体在制备治疗痤疮药物中的应用及一种制剂 |
| KR102764218B1 (ko) * | 2020-10-13 | 2025-02-11 | 신동준 | 반려견의 항암용 재조합 단백질 및 이를 포함하는 반려견을 위한 항암용 조성물 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| JPH0822239B2 (ja) * | 1988-07-07 | 1996-03-06 | 株式会社蛋白工学研究所 | 変異ヒト腫傷壊死因子 |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL220113B1 (pl) | 1999-01-15 | 2015-08-31 | Genentech Inc | Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc |
| CA2377585A1 (en) * | 1999-06-28 | 2001-01-04 | Genentech, Inc. | Methods for making apo-2 ligand using divalent metal ions |
| US7091321B2 (en) | 2000-02-11 | 2006-08-15 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of antibody-based fusion proteins |
| US6725230B2 (en) | 2000-07-18 | 2004-04-20 | Aegis Analytical Corporation | System, method and computer program for assembling process data of multi-database origins using a hierarchical display |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| EP1534335B9 (en) | 2002-08-14 | 2016-01-13 | Macrogenics, Inc. | Fcgammariib-specific antibodies and methods of use thereof |
| EP2298805A3 (en) | 2002-09-27 | 2011-04-13 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| DK1562972T3 (da) | 2002-10-15 | 2010-12-06 | Facet Biotech Corp | Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| GB0328261D0 (en) * | 2003-12-05 | 2004-01-07 | Univ Groningen | Improved cytokine design |
| CA2552788C (en) | 2004-01-12 | 2013-09-24 | Applied Molecular Evolution, Inc. | Fc region variants |
| EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| CN101001873B (zh) | 2004-08-04 | 2013-03-13 | 曼璀克生物科技有限责任公司 | Fc区变体 |
| GB0724532D0 (en) * | 2007-12-17 | 2008-01-30 | Nat Univ Ireland | Trail variants for treating cancer |
| DK2604693T3 (en) * | 2008-07-21 | 2016-05-30 | Apogenix Gmbh | Single-chain TNFSF molecules |
| JP5677972B2 (ja) | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
| ES2548030T3 (es) * | 2009-06-01 | 2015-10-13 | Medimmune, Llc | Moléculas con semividas prolongadas y usos de las mismas |
| EP2564188A4 (en) | 2010-04-26 | 2013-09-25 | Merrimack Pharmaceuticals Inc | TESTS FOR ANTI-MEDICATION ANTIBODIES IN THE PRESENCE OF ENDOGENOUS PROTEIN COMPOUNDS OF THE MEDICINAL PRODUCT |
| EP2468764A1 (en) * | 2010-12-24 | 2012-06-27 | Rijksuniversiteit te Groningen | TNF family ligand variants |
| US9822179B2 (en) * | 2011-04-01 | 2017-11-21 | Universitat Stuttgart | Recombinant TNF ligand family member polypeptides with antibody binding domain and uses therefor |
| US20130150566A1 (en) * | 2011-07-06 | 2013-06-13 | Targetpharma Laboratories (Changzhou) Co., Ltd | Tumor-targeted tnf-related apoptosis-inducing ligand's variant and the application thereof |
| NO2776305T3 (cg-RX-API-DMAC7.html) * | 2014-04-23 | 2018-01-27 | ||
| US10428149B2 (en) * | 2015-03-18 | 2019-10-01 | Universitat Stuttgart | Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof |
-
2017
- 2017-03-16 AU AU2017234679A patent/AU2017234679A1/en not_active Abandoned
- 2017-03-16 CA CA3017622A patent/CA3017622A1/en not_active Abandoned
- 2017-03-16 MX MX2018011219A patent/MX2018011219A/es unknown
- 2017-03-16 US US16/084,447 patent/US20190077870A1/en not_active Abandoned
- 2017-03-16 EP EP17713861.7A patent/EP3430034A1/en not_active Withdrawn
- 2017-03-16 WO PCT/US2017/022789 patent/WO2017161173A1/en not_active Ceased
- 2017-03-16 CN CN201780016988.2A patent/CN108884142A/zh active Pending
- 2017-03-16 JP JP2018548878A patent/JP2019518713A/ja active Pending
- 2017-03-16 KR KR1020187029745A patent/KR20180127407A/ko not_active Withdrawn
-
2018
- 2018-08-21 IL IL261267A patent/IL261267A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11919931B2 (en) | Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3) | |
| JP2025063029A5 (cg-RX-API-DMAC7.html) | ||
| RU2010122053A (ru) | Иммуносупрессорные полипептиды и нуклеиновые кислоты | |
| US8927693B2 (en) | Fibronectin based scaffold domain proteins that bind IL-23 | |
| EP3998077B1 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| JP2017527272A5 (cg-RX-API-DMAC7.html) | ||
| JP2017512063A5 (cg-RX-API-DMAC7.html) | ||
| US20230340031A1 (en) | Self-assembling protein nanoparticles with built-in six-helix bundle proteins | |
| JP2019512222A5 (cg-RX-API-DMAC7.html) | ||
| JP2019518713A5 (cg-RX-API-DMAC7.html) | ||
| JP2018510622A5 (cg-RX-API-DMAC7.html) | ||
| PT2697257T (pt) | Proteínas de fusão fc compreendendo novos ligantes ou arranjos | |
| JP2014510518A5 (cg-RX-API-DMAC7.html) | ||
| MX2012002428A (es) | Compuestos de union il-17 y usos medicos de los mismos. | |
| JP7385680B2 (ja) | 変異型ｒｓｖ ｆタンパク質及びその利用 | |
| JP2015504052A5 (cg-RX-API-DMAC7.html) | ||
| JP2014510519A5 (cg-RX-API-DMAC7.html) | ||
| JP2019530441A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2021116182A5 (cg-RX-API-DMAC7.html) | ||
| WO2013065343A1 (ja) | 非ペプチドヒンジ部含有フレキシブル抗体様分子 | |
| US20240182544A1 (en) | Polypeptides targeting dr4 and/or dr5 and related compositions and methods | |
| US20220340629A1 (en) | Myosin Derived Peptides and Related Compounds with Anticoagulant Activities | |
| CN115666522B (zh) | 包含il-2蛋白和cd80蛋白的融合蛋白制剂 | |
| JPWO2022129560A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2021107603A5 (cg-RX-API-DMAC7.html) |